Updates

Date: 10th September, 2026 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock Code : INDOCO Dear Sir/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that UK Medicines and Healthcare products Regulatory Agency (MHRA) had inspected Company’s manufacturing facility at Plant I (solid oral dosage form) located at Goa (“Facility”) from 07th September, 2026 to 09th September, 2026. UK MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations. The Company continues to maintain the highest standards of quality and regulatory compliance. Please find enclosed herewith press release in this regard. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Indoco Remedies Limited Sundeep V. Bambolkar Jt. Managing Director DIN: 00176613 PRESS RELEASE Indoco’s solid dosages facility (Plant I) inspected by the UK-MHRA Mumbai, Sep 11, 2026: Indoco Remedies Limited announced today that the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) inspected its solid dosages manufacturing facility in Goa (Plant I) from September 7 to September 9, 2026. The UK-MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations. Commenting on the development, Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd. said, “This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30% of total international business. The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards. The accolade not only reinforces the trust our global partners place in us, but strengthens our ability to serve patients worldwide.” The facility which manufactures solid dosages and liquid dosages is approved by USFDA, (solid dosages, creams and capsules), TGA-Australia (solid dosages, liquid orals, creams and ointments) and by EU Malta, i.e., MMA - Malta Medicine Authority (solid dosages). The Plant also holds WHO-GMP approval and has successfully faced audit by SAHPRA (for solid dosages). About Indoco Remedies Limited: Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization. The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc. On the international front, Indoco has tie-ups with large generic companies across the globe. For more details on Indoco, you may visit www.indoco.com For Media enquiries please contact: Tel. +91 22 62871000 | E-mail: corpcom@indoco.com